

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4617538

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JED WILTZIUS	09/28/2017
STUART SIEVERS	09/28/2017
RECEIVING PARTY DATA	
Name:	KITE PHARMA, INC.
Street Address:	2225 COLORADO AVENUE
City:	SANTA MONICA
State/Country:	CALIFORNIA
Postal Code:	90404
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15717691
CORRESPONDENCE DATA	
Fax Number:	(310)496-0695
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3107422981
Email:	mtadenuma@kitepharma.com
Correspondent Name:	KITE PHARMA, INC.
Address Line 1:	2225 COLORADO AVENUE
Address Line 4:	SANTA MONICA, CALIFORNIA 90404
ATTORNEY DOCKET NUMBER:	K-1036.02
NAME OF SUBMITTER:	MEGUMI TADENUMA
SIGNATURE:	/Megumi Tadenuma/
DATE SIGNED:	09/28/2017
Total Attachments: 2	
source=K-103602US_Assignment#page1.tif	
source=K-103602US_Assignment#page2.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Jed WILTZIUS**, and **Stuart SIEVERS**, hereby sell and assign to **Kite Pharma, Inc.**, a corporation formed under the laws of Delaware, whose mailing address is 2225 Colorado Avenue, Santa Monica, California 90404 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF** for which one or more applications for patent in the United States of America was filed on September 27, 2017 (also known as United States Application No. 15/717,691 and PCT International Application No. PCT/US2017/053790), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.


The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 138148** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 138148** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 9/28/17


Signature of Inventor: 
Jed WELTZIUS

Date: 9/28/17

Signature of Inventor: 
Stuart SIEVERS

SIGNED on behalf of the said ASSIGNEE,

Kite Pharma, Inc.

By: 

Name: Scott N. Bernstein

Title: Vice President, IP Law and Litigation

Date: 9/28/17